Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.

Autor: Liu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Bone and Soft Tissue Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Li Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Research Institute, Beijing, China., Gao S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiology, Peking University Cancer Hospital and Research Institute, Beijing, China., Mao L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Dai J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Li C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Cui C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Research Institute, Beijing, China., Chi Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Sheng X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Research Institute, Beijing, China., Lai Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Research Institute, Beijing, China., Tan Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Bone and Soft Tissue Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Lian B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Tang B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Yan X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Research Institute, Beijing, China., Li S; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Zhou L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Research Institute, Beijing, China., Wei X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Li J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Research Institute, Beijing, China., Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China., Si L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China. silu15_silu@126.com.
Jazyk: angličtina
Zdroj: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Nov 22; Vol. 9 (1), pp. 318. Date of Electronic Publication: 2024 Nov 22.
DOI: 10.1038/s41392-024-02029-2
Abstrakt: Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma (AM). This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1 toripalimab (tori) for resectable AM. Thirty patients of stage III/IV received neoadjuvant therapy of ori and tori for 12 weeks before surgery, followed by adjuvant treatment with tori for 1 year. Primary endpoints were radiographic and pathological response rates, with secondary endpoints of 1- and 2-year recurrence-free survival (RFS) rates, event-free survival (EFS) rates, and safety. Twenty-seven completed surgery and tori adjuvant treatment and median follow-up was 35.7 months. Radiographic and pathological response rates were 36.7% and 77.8%, with complete response rates of 3.3% and 14.8%, 1- and 2-year RFS rates of 85.2% and 81.5%, and 1- and 2-year EFS rates of 83% and 73%, respectively. Adverse events occurred in all patients, mainly grade 1-2. There was no correlation between PET/CT evaluation and pathological response or progression-free survival/overall survival. Patients with pathological response showed tumor beds with high tertiary lymphoid structures (TLSs) and tumor-infiltrating lymphocytes (TILs). Cytokines and chemokines analysis showed the combination therapy significantly increases the secretion of proinflammatory cytokines and chemokines in both responders and non-responders. Therefore, neoadjuvant ori and tori demonstrated promising antitumor activity with high response rates and high 2-year RFS/EFS for AM with acceptable tolerability.
Competing Interests: Competing interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jun Guo serves consulting/advisory roles in Merck Sharp & Dohme, Roche, Bayer, Novartis, Simcere Pharmaceutical Group and Shanghai Junshi Biosciences. Lu Si has received speakers’ honoraria from MSD, Roche, Novartis, and Shanghai Junshi Biosciences. The remaining authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: